Juva Life Announces Flōs, New Branded Cannabis Flower Line, The Canadian Business Journal

VANCOUVER, British Columbia, September 21, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or “Company”) , a life sciences company with consumer operations in pharmaceutical research and development and cannabis production and distribution, today announced the launch of its new product line, Flōs. This is a branded line of flowers and pre-rolled cannabis products.

Juva CEO and Founder Doug Chloupek said: “With the completion of construction on our growing facility in Stockton, we are pleased to double our production capacity and provide the space to offer the new consumer packaged goods our customers are demanding.”

Flōs is Latin for flower or flower, and the unique beauty of the cannabis flower is fully demonstrated in Juva’s new line of products. Featuring 8-ounce servings, 1-gram servings of pre-rolls, and 0.5-ounce flower products, these meticulously selected varieties are budget-friendly without sacrificing quality.

The Flōs flower line is available throughout California and through Juva Delivery, a division of vertically integrated Juva Life, Inc. A fee-free online payment service. The Flōs Flower line has been approved for licensing by the City of Redwood City and will also be featured in the company’s upcoming retail stores currently under construction.

Each Flōs product begins with the highest quality cannabis cultivars grown in our 30,000 square foot cannabis growing facility in Stockton, California. Once harvested and cured, the material is moved to Juva’s distribution department for final processing and statewide distribution.To find locally available products in the San Francisco Peninsula area, visit access here.

On behalf of the Board of Directors,

-Doug Klopek-

Doug Klopeck, CEO and Founder

Juba Life Co., Ltd.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life uses cutting-edge science to discover, develop and commercialize safe and effective health and medicines for both the cannabis consumer segment and the non-cannabinoid-based medical industry. The company is on track to execute his 2018 roadmap, initially by standardizing cultivation, extraction and formulation to deliver reproducible benefits to consumers. Juva has built on these natural product process chemistry skills and now incorporates discovery pharmacology. The Company will leverage the revenues generated from its retail operations to invest in Juva-019 and Juva-041 consumer and clinical development efforts, as well as other potentially valuable pharmaceuticals with significant consumer product and pharmaceutical applications. Promotes non-cannabinoid bioactive substances. Juva is committed to aligning the cannabis market with the next generation of investment grade business models in the space. For more information, see: https://juvalife.com/.

For more information, please contact:

Juba Life Investor Information

phone number: +1 833-333-5882 (Juba)

Email: [email protected]

forward-looking statements

To the extent that this news release is not historical fact, this news release contains statements and information that may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections and statements regarding future plans, objectives or economic performance or the assumptions underlying any of the foregoing. In some cases, forward-looking statements are “may,” “would,” “could,” “will,” “likely,” “exclude,” and “expect.” can be identified by terms such as , “believe” and “intend”. , “plans”, “forecasts”, “plans”, “estimates”, “outlooks” or other similar expressions relating to the negative of these or matters that are not historical facts. Examples of such statements include, but are not limited to, statements regarding our purpose and business plans. Product development, commercialization strategies and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and the Company’s actual results, performance or performance may differ materially from future results, performance or performance expressed or implied by forward-looking information. It includes other factors that can cause different. risks associated with our future business plans; The risk that we may not be able to secure key personnel; As with all other risks described in our management’s discussion and analysis under the heading “Risks and Uncertainties” for the year ended December 31, 2020, we The risk of not being able to secure funding on terms or the risk of not being able to raise funding at all. Accordingly, readers should not place undue reliance on such forward-looking information. In addition, forward-looking information speaks only as of the date such statements are made. New factors emerge from time to time and it is not possible for our management to predict all such factors, and we may not be able to predict the impact of each such factor, or factor or combination of factors, on our business. It is impossible to assess in advance how much it will be affected. , actual results may differ materially from those contained in the forward-looking information. We do not use forward-looking information to reflect information or events after the date they were made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. shall not be obliged to update to

CSE does not take responsibility for the adequacy or accuracy of this release.

CBJ Newsmaker